Citations

Showing 10 of 108152 citations.

Disruption of Robo2-Baiap2 integrated signaling drives cystic disease
Li, Qinggang, Cui, Shaoyuan , Ma, Qian , Liu, Ying , Geng, Guangrui , Agborbesong, Ewud , Ren, Chongyu, Wei, Kai , Yang, Jurong , Bai, Xueyuan , Xie, Yuansheng, Yu, Hongyu, Wei, Kai, Zhang, Yingjie , Cai, Guangyan , Li, Xiaogang , Chen, Xiangmei

Mayo Clinic

JCI Insight | September 18, 2019 | Volume: 4 | Issue: 18 | Pages: No page available

10.1172/jci.insight.127602 | PMID 31534052 Get It

Hereditary renal cystic diseases are characterized by defects in primary cilia of renal tubular epithelial cells and abnormality of tubular epithelium, which ultimately result in the development of renal cysts. However, the mechanism leading from abnormality of the tubular epithelium to cystogenesis is not well understood. In this report, we demonstrate a critical role for Robo2 in regulating epithelial development, including ciliogenesis, polarization, and differentiation. We found that Robo2 deficiency results in cystic kidneys, and the cyst cells showed defective cilia and polarity defects in tubular epithelium. The cyst cells, less than terminally differentiated, continue to proliferate. We further established that Robo2 works with p53 as well as polarity and ciliary proteins (Par3, PKCς, ZO-2, and Claudin-2) to regulate these processes. Robo2 binds to Baiap2 (also known as IRSp53) through the IRSp53/MIM homology domain in renal epithelial cells. This binding allows Robo2 to phosphorylate MDM2 at Ser166 via Baiap2 and maintain p53 homeostasis. Disruption of the Robo2-Baiap2 complex causes MDM2 to be subjected to dephosphorylation, leading to a high level of active p53, and initiated p53-mediated cellular senescence via p21 and decreased the expression of ZO-1, ZO-2, PKCς, Par3, and Claudin-2 proteins, resulting in defects in epithelial development, including ciliogenesis, polarization, and differentiation. Importantly, double knockout of Robo2 and p53 rescued all the epithelial defects in kidneys compared with those in Robo2 -knockout kidneys. Taken together, the present results demonstrate that Robo2 deficiency causes renal cystic disease, which is largely dependent on defective Robo2-Baiap2 integrated signaling in kidneys.
Effect of 3-Dimensional Virtual Reality Models for Surgical Planning of Robotic-Assisted Partial Nephrectomy on Surgical Outcomes
Shirk, Joseph D. , Thiel, David D. , Wallen, Eric, Linehan, Jennifer, White, Wesley M. , Badani, Ketan K. , Porter, James

Mayo Clinic

JAMA Network Open | September 18, 2019 | Volume: 2 | Issue: 9 | Pages: e1911598

10.1001/jamanetworkopen.2019.11598 | PMID 31532520 Get It

Systematic review of patient-reported measures of treatment burden in stroke
Gallacher, Katie , Quinn, Terry, Kidd, Lisa , Dillon, Megan, Elliot, Jennifer, Johnston, Natalie R., Erwin, Patricia J., Mair, Frances S , Gallacher, Katie I , Eton, David, Quinn, Terry, Eton, David T. , Johnston, Natalie

Mayo Clinic

BMJ Open | September 18, 2019 | Volume: 9 | Issue: 9 | Pages: e029258

10.1136/bmjopen-2019-029258 | PMID 31533946 Get It

Objectives Treatment burden is the workload of healthcare for people with long-term conditions (LTC) and its impact on well-being. A method of measurement is required to identify those experiencing high burden and to measure intervention efficacy. Our aim was to identify, examine and appraise validated patient-reported measures (PRMs) of treatment burden in stroke. Here, stroke serves as an exemplar LTC of older adults. Design A systematic review of published studies that describe the development and validation of PRMs measuring treatment burden in stroke survivors. Data sources We searched MEDLINE, Embase, CINAHL and PsycINFO electronic databases. Eligibility criteria Studies published between January 2000 and 12 April 2019 inclusive, in English language. No restrictions were set based on clinical setting or geographical location. Data extraction and synthesis Screening, data extraction and quality appraisal were conducted by two independent reviewers. Content of the PRMs was compared with a published taxonomy of treatment burden. Quality appraisal was conducted using International Society for Quality of Life Research standards. Results From 3993 articles, 6 relevant PRMs were identified: 3 were stroke specific: The Satisfaction with Stroke Care questionnaire; The Stroke Patient-Reported Outcome Measure and The Barriers to Physical Activity after Stroke scale. Three were generic but validated in stroke: The WHO Quality of Life-100; The Patient’s Questionnaire on Participation in Discharge Planning and The Chao Perception of Continuity scale. None comprehensively measured treatment burden. Examples of omitted burdens included developing coping strategies, managing finances and returning to driving. The most notable issue regarding quality appraisal was that three PRMs lacked any underpinning qualitative research relevant to the sample. Conclusion There is a need to develop a comprehensive PRM of treatment burden for use in stroke, with potential for use in other older populations.
Comment on: “Persistent-postural perceptual dizziness (PPPD): Yes, it is a psychosomatic condition!”
Staab, Jeffrey P.

Mayo Clinic

Journal of Vestibular Research | September 18, 2019 | Volume: 33 | Issue: 4 | Pages: 283-285

10.3233/ves-190680 | PMID 31561402 Get It

Psychometric assessment of the health-related productivity questionnaire (HRPQ) among women with endometriosis
Pokrzywinski, Robin , Soliman, Ahmed M. , Chen, Jun , Snabes, Michael C., Agarwal, Sanjay K. , Coddington, Charles C. , Coyne, Karin S. , Coddington, Charles

Mayo Clinic

Expert Review of Pharmacoeconomics & Outcomes Research | September 18, 2019 | Volume: 20 | Issue: 5 | Pages: 531-539

10.1080/14737167.2019.1662301 | PMID 31530044 Get It

Going Beyond “Not Enough Time”: Barriers to Preparing Manuscripts for Academic Medical Journals
Oshiro, June , Caubet, Suzanne L., Viola, Kelly E., Huber, Jill M. , Oshiro, June

Mayo Clinic

Teaching and Learning in Medicine | September 18, 2019 | Volume: 32 | Issue: 1 | Pages: 71-81

10.1080/10401334.2019.1659144 | PMID 31530189 Get It

The relationship between obstructive sleep apnoea and postoperative delirium and pain: an observational study of a surgical cohort
Strutz, Patricia , Tzeng, William S. , Arrington, Brianna, McKinnon, Sherry, Abdallah, Arbi Ben , Haroutounian, Simon , Kronzer, Vanessa L. , Avidan, Michael Simon

Mayo Clinic

Anaesthesia | September 18, 2019 | Volume: 74 | Issue: 12 | Pages: 1542-1550

10.1111/anae.14855 | PMID 31531850 Get It

Summary Patients with obstructive sleep apnoea are at increased risk of adverse postoperative outcomes, such as cardiac and respiratory complications. It has been hypothesised that obstructive sleep apnoea also increases the risk for postoperative delirium and acute postoperative pain. We conducted a retrospective, observational study investigating the relationship of obstructive sleep apnoea with postoperative delirium and acute postoperative pain severity. Patients were classified as being at high risk for obstructive sleep apnoea if they had been diagnosed with this condition, or if they were positive for more than four factors using the ‘ STOP ‐ BANG ’ screening tool. Adjusted logistic regression was used to investigate the association between obstructive sleep apnoea and postoperative delirium, and multivariable linear regression to study the relationship between obstructive sleep apnoea and postoperative pain severity. The incidence of postoperative delirium was 307 in 1441 patients (21.3%; 95% CI 19.2–23.5%). In unadjusted analysis, high risk for obstructive sleep apnoea was associated with delirium, with an odds ratio (95% CI ) of 1.77 (1.22–2.57; p = 0.003). After adjustment for pre‐specified variables, the association was not statistically significant with odds ratio 1.34 (0.80–2.23; p = 0.27). The mean ( SD ) maximum pain (resting or provoked) reported for the entire cohort was 63.8 (27.9) mm on a 0–100 mm visual analogue scale. High risk for obstructive sleep apnoea was not associated with postoperative pain severity (β‐coefficient 2.82; 95% CI , −2.34–7.97; p = 0.28). These findings suggest that obstructive sleep apnoea is unlikely to be a strong risk factor for postoperative delirium or acute postoperative pain severity.
Analysis of Sinonasal Microbiota in Exacerbations of Chronic Rhinosinusitis Subgroups
Vandelaar, Laura J., Hanson, Blake , Marino, Michael J. , Luong, Amber , Arias, César A. , Citardi, Martin J. , Yao, William C. , Arias, César A. , Ramakrishnan, Vijay R

Mayo Clinic

OTO Open | September 17, 2019 | Volume: 3 | Issue: 3 | Pages: No page available

10.1177/2473974x19875100 | PMID 31555757 Get It

Objective Microbiome analyses now allow precise determination of the sinus microbiota of patients with exacerbations of chronic rhinosinusitis (CRS). The aim of this report is to describe the sinus microbiota of acute exacerbations in CRS clinical subgroups (with nasal polyps [CRSwNP], without nasal polyps [CRSsNP], and allergic fungal rhinosinusitis [AFRS]). Study Design Retrospective chart review. Setting Tertiary rhinology practice. Subjects and Methods A retrospective review was performed of all patients whose sinus microbiota were assayed via a commercially available microbiome technology during an acute CRS exacerbation during the 2‐year period ending December 31, 2016. All samples were sinus aspirates collected under endoscopic visualization in clinic. Results Samples from a total of 134 patients (65 CRSsNP, 55 CRSwNP, and 14 AFRS) were reviewed. The observed richness (number of taxa >2% relative abundance) ranged between 1 and 11 taxa, with an average of 3 taxa per specimen. The most common bacteria in all groups were Staphylococcal spp (including Staphylococcus aureus ), Streptococcus spp, Pseudomonas spp, and Escherichia spp. S aureus had an increased prevalence in CRSsNP and AFRS as compared with CRSwNP. Otherwise, the sinus microbiota were markedly similar among all 3 clinical subgroups. Conclusions Many bacterial types are identified during acute CRS exacerbation according to DNA‐based detection techniques. Bacterial richness was remarkably low in all samples. Few differences in the patterns among clinical subgroups were observed. Further investigation is warranted to determine the clinical significance of these observations and their role in current clinical algorithms.
Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome
Yadav, Siddhartha , Hu, Chunling , Hart, Steven N. , Hillman, David, Lee, Kun Y. , Gnanaolivu, Rohan , Na, Jie , Polley, Eric C. , Kohli, Manish , Yadav, Siddhartha , Hu, Chunling , Hillman, David W. , Couch, Fergus J.

Mayo Clinic

JCO Precision Oncology | September 17, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-12

10.1200/po.19.00067 | PMID 32923857 Get It

PURPOSE To compare the prevalence of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castrate-resistant prostate cancer (mCRPC) and assess the impact of mutations on progression to castration resistance and overall survival. METHODS Targeted sequencing of germline DNA from 704 men (221 at the time of mHSPC and 483 at the time of mCRPC) enrolled in two advanced prostate cancer registries at Mayo Clinic between 2003 and 2013 was performed for 21 predisposition genes. Frequencies of pathogenic mutations were compared in patients and reference controls to identify genes enriched in metastatic prostate cancer. Multivariable Cox proportional hazards regression was used to identify predictors of progression to mCRPC and overall survival. RESULTS Sixty-eight germline mutations in 12 genes were identified in 66 men (9.4%). Mutations in ATM, BRCA2, CHEK2, FANCM, and TP53 were significantly enriched (odds ratio greater than 2.0) in the metastatic cohorts compared with reference controls. The frequency of germline mutations was similar for patients with mHSPC and mCRPC (11.8% v 8.3%; P = .16). The median time to progression from mHSPC to mCRPC was 23.1 and 32.5 months for patients with and without mutations, respectively ( P = .96). Although older age at diagnosis, Gleason score greater than 7, elevated alkaline phosphatase level, and high volume of disease were associated with shorter duration of progression to mCRPC and poor overall survival, mutation status was not (progression to mCRPC hazard ratio, 0.81; 95% CI, 0.61 to 1.09; P = .17; overall survival hazard ratio, 1.00; 95% CI, 0.75 to 1.34; P = .98). CONCLUSION Similarly elevated rates of germline predisposition gene mutations in mHSPC and mCRPC suggest that germline genetic testing may help to guide medical management for all patients with advanced metastatic prostate cancer. Mutation status was not associated with shorter progression to mCRPC or poor overall survival.